Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) announced the successful completion of its analytical reference standard preparation program for A83B4C63, the active pharmaceutical ingredient supporting its lead oncology candidate, ONC010. The program, completed in collaboration with Dalton Pharma Services, established a qualified reference standard to support analytical testing, manufacturing consistency, quality control and future regulatory and clinical activities.
This milestone strengthens the company's chemistry, manufacturing and controls (CMC) framework and follows recent progress in API manufacturing, precursor scale-up, analytical method development and chiral purity testing. Onco-Innovations said the reference standard program supports its broader strategy of advancing ONC010 toward clinical readiness while ongoing analytical development efforts continue across stability testing, impurity profiling, formulation characterization and quality control systems.
The completion of the reference standard program is a critical step in the drug development process, as it ensures that the API can be consistently manufactured and tested to meet regulatory standards. For a company focused on oncology, where precision and reliability are paramount, this achievement signals a move closer to clinical trials and potential commercialization. The news is particularly significant given Onco-Innovations' exclusive worldwide license to patented technology targeting solid tumours, as noted in the full press release.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Its mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours. With this latest development, Onco-Innovations is positioning itself to potentially address unmet medical needs in oncology, a field where new treatment options are constantly sought.
Investors and stakeholders can follow the latest news and updates relating to ONNVF in the company's newsroom at https://ibn.fm/ONNVF. The reference standard program completion not only enhances the company's CMC capabilities but also builds confidence in the reproducibility and quality of ONC010, which is essential for regulatory submissions and eventual patient use.
